Alphagan Related Published Studies
Well-designed clinical trials related to Alphagan (Brimonidine)
Meta-analysis of randomized controlled trials comparing timolol with brimonidine in the treatment of glaucoma. [2008.04]
Effect of brimonidine tartrate 0.15% on scotopic pupil: controlled trial. [2007.10]
Effect of Brimonidine Tartrate 0.15% on Scotopic Pupil-Controlled Trial. [2007.09.27]
Effect of prophylactic brimonidine instillation on bleeding during strabismus surgery in adults. [2007.09]
Effects of topical clonidine versus brimonidine on choroidal blood flow and intraocular pressure during squatting. [2007.09]
Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%. [2007.07]
Comparing the fixed combination brimonidine-timolol versus fixed combination dorzolamide-timolol in patients with elevated intraocular pressure. [2007.04]
Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. [2006.09]
The safety and intraocular pressure-lowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium-1. [2006.08]
Brimonidine 0.2% versus brimonidine Purite 0.15%: prophylactic effect on iop elevation after Nd:YAG laser posterior capsulotomy. [2006.06]
Efficacy and tolerability of 0.2% brimonidine tartrate for the treatment of acute non-arteritic anterior ischemic optic neuropathy (NAION): a 3-month, double-masked, randomised, placebo-controlled trial. [2006.05]
A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension. [2006.04]
Comparative analysis of the effects of brimonidine and dorzolamide on ocular blood flow velocity in patients with newly diagnosed primary open-angle glaucoma. [2006.04]
Comparison of the effects of brimonidine 0.2% and timolol 0.5% on retinal nerve fiber layer thickness in ocular hypertensive patients: a prospective, unmasked study. [2005.12]
Brimonidine 0.15% versus apraclonidine 0.5% for prevention of intraocular pressure elevation after anterior segment laser surgery. [2005.09]
12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. [2005.09]
Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. [2005.08]
Brimonidine versus dapiprazole: Influence on pupil size at various illumination levels. [2005.07]
24-hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects. [2005.04]
Latanoprost or brimonidine as treatment for elevated intraocular pressure: multicenter trial in the United States. [2005.04]
Comparing brimonidine 0.2% to apraclonidine 1.0% in the prevention of intraocular pressure elevation and their pupillary effects following laser peripheral iridotomy. [2005.03]
Effect of prophylactic brimonidine on bleeding complications after cataract surgery. [2005.03]
Comparison of additional intraocular pressure-lowering effects of latanoprost vs brimonidine in primary open-angle glaucoma patients with intraocular pressure uncontrolled by timolol-dorzolamide combination. [2005.02]
Brimonidine 0.2% vs unoprostone 0.15% both added to timolol maleate 0.5% given twice daily to patients with primary open-angle glaucoma or ocular hypertension. [2005.01]
The efficacy of topical administration of brimonidine to reduce ischaemia in the very early stage of diabetic retinopathy in good controlled type-2 diabetes mellitus. [2004.12]
Efficacy and safety of the latanoprost/timolol maleate fixed combination vs concomitant brimonidine and latanoprost therapy. [2004.10]
Diurnal intraocular pressure and blood pressure with two dosing regimens of brimonidine in normal tension glaucoma. [2004.09]
The comparative cardiovascular, pulmonary, ocular blood flow, and ocular hypotensive effects of topical travoprost, bimatoprost, brimonidine, and betaxolol. [2004.08]
Effect of topical brinzolamide 1% and brimonidine 0.2% on intraocular pressure after phacoemulsification. [2004.08]
Brimonidine purite 0.15% versus dorzolamide 2% each given twice daily to reduce intraocular pressure in subjects with open angle glaucoma or ocular hypertension. [2004.07]
A comparison of the fixed combination of latanoprost and timolol with the unfixed combination of brimonidine and timolol in patients with elevated intraocular pressure. A six month, evaluator masked, multicentre study in Europe. [2004.07]
[Efficiency of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers] [2004.04]
Comparison of the safety and efficacy of dorzolamide 2% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. [2004.04]
Dorzolamide/Timolol fixed combination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure: a 3-month comparison of efficacy, tolerability, and patient-reported measures. [2004.04]
The safety and efficacy of unoprostone 0.15% versus brimonidine 0.2%. [2004.04]
Aqueous humor flow in normal human eyes treated with brimonidine and dorzolamide, alone and in combination. [2004.02]
Randomised controlled trial comparing the effect of brimonidine and timolol on visual field loss after acute primary angle closure. [2004.01]
Efficacy and safety of brimonidine, dorzolamide and latanoprost as adjunctive therapy in primary open angle glaucoma. [2003.12]
Efficacy of brimonidine 0.2% in controlling acute postoperative intraocular pressure elevation after phacoemulsification. [2003.12]
Contrast sensitivity improves after brimonidine therapy in primary open angle glaucoma: a case for neuroprotection. [2003.12]
Short posterior ciliary artery, central retinal artery, and choroidal hemodynamics in brimonidine-treated primary open-angle glaucoma patients. [2003.12]
Evaluation of the comfort of Alphagan P compared with Alphagan in irritated eyes. [2003.11]
A short-term study of the additive effect of latanoprost 0.005% and brimonidine 0.2%. [2003.09]
Effect of brimonidine on intraocular pressure in normal tension glaucoma: a short term clinical trial. [2003.08]
Evaluation of neuroprotective qualities of brimonidine during LASIK. [2003.08]
Efficacy and safety of timolol maleate/latanoprost fixed combination versus timolol maleate and brimonidine given twice daily. [2003.06]
The efficacy and safety of brimonidine 0.2% compared with timolol 0.5% in glaucoma: a randomized clinical trial on Taiwanese patients. [2003.05]
Unoprostone as adjunctive therapy to timolol: a double masked randomised study versus brimonidine and dorzolamide. [2003.05]
[The effect of brimonidine on postoperative hypertonia after an extracapsular cataract extraction] [2003.04]
The effects of latanoprost and brimonidine on blood flow velocity of the retrobulbar vessels: a 3-month clinical trial. [2003.04]
The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension. [2003.04]
Comparison of brimonidine/latanoprost and timolol/dorzolamide: two randomized, double-masked, parallel clinical trials. [2003.03]
Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability. [2003.03]
A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. [2003.02]
Brimonidine Purite and bimatoprost compared with timolol and latanoprost in patients with glaucoma and ocular hypertension. [2003.01]
Ocular perfusion pressure and visual field indice modifications induced by alpha-agonist compound (clonidine 0.125%, apraclonidine 1.0% and brimonidine 0.2%) topical administration. An acute study on primary open-angle glaucoma patients. [2003.01]
Changes in intraocular pressure and ocular perfusion pressure after latanoprost 0.005% or brimonidine tartrate 0.2% in normal-tension glaucoma patients. [2002.12]
Effect of single and multiple doses of 0.2% brimonidine tartrate in the glaucomatous Beagle. [2002.12]
Effect of latanoprost 0.005% and brimonidine tartrate 0.2% on pulsatile ocular blood flow in normal tension glaucoma. [2002.11]
Effect of prophylactic brimonidine on bleeding complications and flap adherence after laser in situ keratomileusis. [2002.07]
Cardiovascular effects of timolol maleate, brimonidine or brimonidine/timolol maleate in concomitant therapy. [2002.06]
Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. [2002.04]
Intraocular pressure-lowering effects of latanoprost and brimonidine therapy in patients with open-angle glaucoma or ocular hypertension: a randomized observer-masked multicenter study. [2002.04]
Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering. [2002.02]
A short term study of the additive effect of timolol and brimonidine on intraocular pressure. [2002.01]
A comparison of the short-term hypotensive effects and side effects of unilateral brimonidine and apraclonidine in patients with elevated intraocular pressure. [2002.01]
Latanoprost and brimonidine: therapeutic and physiologic assessment before and after oral nonsteroidal anti-inflammatory therapy. [2002.01]
[The ocular hypotensive effect and safety of 0.2% brimonidine] [2001.12]
A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial. [2001.12]
Effect of topical brimonidine on intraocular pressure after small incision cataract surgery. [2001.08]
Comparison of the clinical success and quality-of-life impact of brimonidine 0.2% and betaxolol 0.25 % suspension in patients with elevated intraocular pressure. [2001.07]
Effect of brimonidine tartrate on ocular hemodynamics in healthy volunteers. [2001.06]
Brimonidine 0.2% given two or three times daily versus timolol maleate 0.5% in primary open-angle glaucoma. [2001.06]
Brimonidine 0.2% versus apraclonidine 0.5% for prevention of intraocular pressure elevations after anterior segment laser surgery. [2001.06]
The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension. [2001.05]
Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension. [2001.04]
Aqueous humor flow in normal human eyes treated with brimonidine and timolol, alone and in combination. [2001.04]
Therapeutic success of latanoprost 0.005% compared to brimonidine 0.2% in patients with open-angle glaucoma or ocular hypertension. [2000.12]
Brimonidine and postoperative pressure spikes in cataract surgery. [2000.10]
Comparison of the clinical success rates and quality of life effects of brimonidine tartrate 0.2% and betaxolol 0.25% suspension in patients with open-angle glaucoma and ocular hypertension. Brimonidine Outcomes Study Group II. [2000.10]
Effect of 0.2% brimonidine in preventing intraocular pressure elevation after Nd:YAG laser posterior capsulotomy. [2000.07]
Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure. [2000.06]
Clinical success and quality of life with brimonidine 0.2% or timolol 0.5% used twice daily in glaucoma or ocular t hypertension: a randomized clinical trial. Brimonidine Outcomes Study Group I. [2000.06]
Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2. [2000.06]
Comparative acute effects of brimonidine 0.2% versus dorzolamide 2% combined with beta-blockers in glaucoma. [2000.04]
Comparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma. ALPHAGAN/XALATAN Study Group. [2000.04]
The effect of brimonidine tartrate on retinal blood flow in patients with ocular hypertension. [2000.03]
Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Brimonidine Study Group II. [2000.01]
The efficacy of 0.2% brimonidine for preventing intraocular pressure rise following argon laser trabeculoplasty. [1999.12]
The effect of brimonidine tartrate on retinal blood flow in patients with ocular hypertension [corrected] [1999.12]
Control of intraocular pressure elevations after argon laser trabeculoplasty: comparison of brimonidine 0.2% to apraclonidine 1.0%. [1999.10]
Use of topical brimonidine to prevent intraocular pressure elevations following Nd:YAG-laser posterior capsulotomy. [1999.09]
Effects of 0.2% brimonidine on ocular anterior structures. [1999.08]
Efficacy of brimonidine 0.2% as adjunctive therapy for patients with glaucoma inadequately controlled with otherwise maximal medical therapy. [1999.08]
Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. [1999.07]
Comparison of the early effects of brimonidine and apraclonidine as topical ocular hypotensive agents. [1999.05]
Apraclonidine 0.5% versus brimonidine 0.2% for the control of intraocular pressure elevation following anterior segment laser procedures. [1999.03]
Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group. [1999.01]
The short-term effect of adding brimonidine 0.2% to timolol treatment in patients with open-angle glaucoma. [1999]
Effect of brimonidine tartrate on ocular hemodynamic measurements. [1998.12]
Comparison of the efficacy of apraclonidine and brimonidine as aqueous suppressants in humans. [1998.11]
|
